期刊
PHARMACOGENOMICS
卷 12, 期 4, 页码 503-514出版社
FUTURE MEDICINE LTD
DOI: 10.2217/PGS.10.200
关键词
cytarabine; cytidine deaminase; hematotoxicity; pharmacogenomics
资金
- German Jose Carreras Leukemia foundation e.V [DJCI S R08/11]
Aim: To adopt an individualized approach to assess cytarabine (ara-C) hematotoxicity, we studied the relationship between pharmacogenetic variability in the cytidine deaminase gene (CDA) and ara-C toxicity in native peripheral blood mononuclear cells from 100 healthy volunteers. Materials & methods: Peripheral blood mononuclear cells were incubated for 48 h with 3 mu M ara-C, and cell viability was analyzed by flow cytometry with and without the addition of an equilibrative nucleoside transporter transport inhibitor. CDA promoter and exonic variants were genotyped to derive haplotypes for the CDA gene. Results: Significant between-subject variability was observed in ara-C toxicity (21-fold with 40.1% coefficient of variation compared with 1.2-fold within-subject variability [9.6% coefficient of variation]). Inhibition of hENT1 reversed ara-C cytotoxicity. The linked CDA promoter variants -451C>T, -92A>G, -31Del and the exonic 79A>C variant were associated with ara-C toxicity (p < 0.05). CDA*2A haplotype was associated with ara-C toxicity (p = 0.03). Conclusion: Genetic polymorphisms within CDA may be risk factors for ara-C-induced hematotoxicity.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据